GoAI
Get started
Janux Therapeutics, Inc. logo

Janux Therapeutics, Inc.

JANX

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$17.37

+$0.11 · +0.64%

Aug 21, 3:55 PM ET

JANX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

17

Overpriced

Momentum

47

Neutral

Sentiment

68

Bullish

Risk resilience

30

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
David Alan Campbell
Listed since
Jun 11, 2021
Employees
113

Market position

Volume
520.04K
0.52× average
Average volume
997.15K
Average daily volume
Market cap
1.06B USD
Beta
2.51
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
824.95M USD
P/E (TTM)
-10.6×
P/B (TTM)
1.18×
P/S (TTM)
33.27×
EV / EBITDA
-7.39×
Earnings yield
-13.29%
Free cash flow yield
-9.74%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
68.91%
Operating margin
-450.30%
Net margin
-321.81%
Return on equity
-11.88%
Return on assets
-11.28%
Return on invested capital
-16.01%

Financial health

Debt / equity
0.02×
Current ratio
39.04×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends257%-410%-1077%-1743%Gross margin, FY2021: -621.39%Gross margin, FY2022: 90.23%Gross margin, FY2023: 75.81%Gross margin, FY2024: 80.54%Gross margin, FY2025: 79.71%Operating margin, FY2021: -905.39%Operating margin, FY2022: -779.04%Operating margin, FY2023: -902.87%Operating margin, FY2024: -933.58%Operating margin, FY2025: -1576.67%Net margin, FY2021: -898.32%Net margin, FY2022: -732.22%Net margin, FY2023: -721.18%Net margin, FY2024: -651.62%Net margin, FY2025: -1136.25%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -621.39%. Gross margin FY2022 90.23%. Gross margin FY2023 75.81%. Gross margin FY2024 80.54%. Gross margin FY2025 79.71%. Operating margin FY2021 -905.39%. Operating margin FY2022 -779.04%. Operating margin FY2023 -902.87%. Operating margin FY2024 -933.58%. Operating margin FY2025 -1576.67%. Net margin FY2021 -898.32%. Net margin FY2022 -732.22%. Net margin FY2023 -721.18%. Net margin FY2024 -651.62%. Net margin FY2025 -1136.25%.

Income trends

Revenue

10M USD-5.55%

Operating income

−157.67M USD-59.51%

Net income

−113.63M USD-64.69%
Income trends across reported periods27.41M USD−39.89M USD−107.19M USD−174.49M USDRevenue, FY2021: 3.64M USDRevenue, FY2022: 8.61M USDRevenue, FY2023: 8.08M USDRevenue, FY2024: 10.59M USDRevenue, FY2025: 10M USDOperating income, FY2021: −32.93M USDOperating income, FY2022: −67.09M USDOperating income, FY2023: −72.98M USDOperating income, FY2024: −98.85M USDOperating income, FY2025: −157.67M USDNet income, FY2021: −32.67M USDNet income, FY2022: −63.06M USDNet income, FY2023: −58.29M USDNet income, FY2024: −68.99M USDNet income, FY2025: −113.63M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 3.64M USD. Revenue FY2022 8.61M USD. Revenue FY2023 8.08M USD. Revenue FY2024 10.59M USD. Revenue FY2025 10M USD. Operating income FY2021 −32.93M USD. Operating income FY2022 −67.09M USD. Operating income FY2023 −72.98M USD. Operating income FY2024 −98.85M USD. Operating income FY2025 −157.67M USD. Net income FY2021 −32.67M USD. Net income FY2022 −63.06M USD. Net income FY2023 −58.29M USD. Net income FY2024 −68.99M USD. Net income FY2025 −113.63M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue10M USD10.59M USD8.08M USD8.61M USD3.64M USD
Cost of goods sold2.03M USD2.06M USD1.96M USD841K USD26.24M USD
Gross profit7.97M USD8.53M USD6.13M USD7.77M USD−22.6M USD
Research and development125.9M USD68.39M USD54.92M USD53.44M USD26.24M USD
Selling, general, and administrative41.77M USD41.05M USD26.14M USD22.26M USD10.33M USD
Operating expenses165.64M USD107.38M USD79.11M USD74.86M USD10.33M USD
Interest income44.04M USD29.85M USD14.69M USD4.03M USD257K USD
Depreciation and amortization2.03M USD2.06M USD1.96M USD841K USD113K USD
Operating income−157.67M USD−98.85M USD−72.98M USD−67.09M USD−32.93M USD
Net income−113.63M USD−68.99M USD−58.29M USD−63.06M USD−32.67M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+12.76%
11 comparable reports
Latest EPS result
-0.35
Estimate -0.25 · Miss by 39.28%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.21-0.37-0.53-0.69Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual -0.36, estimate -0.49, surprise +26.53%, Beat. Q2 2025, reported May 8, 2025: actual -0.38, estimate -0.43, surprise +11.63%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.55, estimate -0.48, surprise -14.58%, Miss. Q4 2025, reported Nov 6, 2025: actual -0.39, estimate -0.6, surprise +35.00%, Beat. Q1 2026, reported Feb 26, 2026: actual -0.51, estimate -0.65, surprise +21.54%, Beat. Q2 2026, reported May 7, 2026: actual -0.39, estimate -0.52, surprise +25.03%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.35, estimate -0.251, surprise -39.28%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.48, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates20.59M13.75M6.91M70.83KQ1 '25EstimateQ2 '25EstimateQ3 '25EstimateQ4 '25No estimateQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual —, estimate 1.82M USD, surprise —, Comparison unavailable. Q2 2025, reported May 8, 2025: actual —, estimate 660K USD, surprise —, Comparison unavailable. Q3 2025, reported Aug 7, 2025: actual —, estimate 300K USD, surprise —, Comparison unavailable. Q4 2025, reported Nov 6, 2025: actual 10M USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 26, 2026: actual 7.88M USD, estimate 83.33K USD, surprise +9356.04%, Beat. Q2 2026, reported May 7, 2026: actual 3.73M USD, estimate 4.36M USD, surprise -14.32%, Miss. Q3 2026, reported Aug 6, 2026: actual 10.27M USD, estimate 19.07M USD, surprise -46.17%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 8.03M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

15 ratings
Strong buy00%
Buy1173%
Hold320%
Sell17%
Strong sell00%

Recent analyst actions

12 institutions
Jones TradingmaintainBuy
UBSdowngradeBuyNeutral

JANX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding JANX

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
34.98M
Weight
0.31%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
19.19M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
19.17M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
8.62M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
7.44M
Weight
0.07%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
6.96M
Weight
0.05%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
4.07M
Weight
0.02%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
3.68M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%

Continue in GoAI

Research JANX

research.disclaimer